Research programme: vascular endothelial growth factor b - PhiloGeneAlternative Names: BiCentis; BiVastin; VEGFb
Latest Information Update: 22 Jun 2011
At a glance
- Originator University of Bristol
- Developer Alcon; PhiloGene
- Class Cytokines
- Mechanism of Action Vascular endothelial growth factor receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Retinal disorders